Conclusion
The goal in the treatment of early Parkinson's disease is to provide effective control of symptoms while delaying the development of motor fluctuations and dyskinesia. Using the currently available treatment options, treatment strategies for early Parkinson's disease have evolved to focus more on maintaining lower daily doses of levodopa and using combination therapy, primarily with dopamine agonists and MAO-B inhibitors, in an attempt to delay the development of motor complications. Research is ongoing to identify new symptomatic and neuroprotective treatment options for early Parkinson's disease, including new dopaminergic compounds as well as those that do not focus directly on dopamine depletion. Several studies have focused on the potential benefits of earlier exercise intervention. Further research is needed to identify a definitely neuroprotective agent for Parkinson's disease, to develop new treatment options with more consistent benefit and fewer adverse events including motor complications, and to determine the full spectrum of benefits achieved with exercise, the most beneficial form of exercise in early Parkinson's disease and the potential of exercise to have a disease-modifying effect.